Form 4: Sage Therapeutics Officer Reports Routine RSU Vesting and Tax Withholding

Michael C. Quirk, Chief Scientific Officer of Sage Therapeutics, Inc., reported a routine disposition of 113 shares of common stock for tax withholding purposes following the vesting of restricted stock units.

Summary

• Michael C. Quirk, Chief Scientific Officer and Interim Head of R&D at Sage Therapeutics, Inc. (SAGE), filed a Form 4 reporting a transaction on June 24, 2025.
• The transaction involved the disposition of 113 shares of Sage Therapeutics common stock at a price of $9.22 per share.
• This disposition was specifically for tax withholding obligations related to the vesting of restricted stock units (RSUs).
• On June 24, 2025, Mr. Quirk vested 338 shares of time-based RSUs that were granted on October 28, 2021, under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan.
• The RSU grant initially vested 25% on September 24, 2022, and continues to vest quarterly in twelve equal installments.
• Following this transaction, Mr. Quirk beneficially owns 30,461 shares of Sage Therapeutics common stock.
• A Power of Attorney document was also filed, authorizing specific individuals to prepare and sign SEC filings on behalf of Michael C. Quirk.

Sentiment

Score: 5

Explanation: The document is a routine compliance filing detailing an insider's equity transaction related to compensation, which is neutral in sentiment.

Positives

• The vesting of 338 restricted stock units (RSUs) represents earned compensation for Michael C. Quirk, indicating continued long-term incentive alignment with company performance.

Future Outlook

The document does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook, as it is a compliance filing for an individual insider transaction.

Industry Context

This Form 4 filing is a routine compliance disclosure for an individual executive's equity compensation and does not provide broader insights into industry trends or competitive positioning for Sage Therapeutics.

Related Party Transactions

• The vesting of restricted stock units (RSUs) is part of the reporting person's compensation package, which is a common form of related party transaction between a company and its executives.

Stakeholder Impact

• Shareholders: Minimal direct impact, as this is a routine, non-discretionary transaction for tax purposes related to executive compensation.
• Employees: No direct impact on general employees, but it reflects standard executive compensation practices.

Next Steps

• The remaining unvested portions of the RSU grant from October 28, 2021, are expected to continue vesting quarterly in equal installments.

Key Dates

Keywords

Sage Therapeutics, SAGE, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Michael C. Quirk, Officer Transaction